SELECT MDS-1
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 550 patients (estimated)
- Sponsors
- Syros Pharmaceuticals
- Tags
- Antimetabolites, Hypomethylating Agents (HMA), Retinoic Acid Receptor Alpha (RAR-α) / NR1B1, Placebo, Randomization
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1367
- NCT Identifier
- NCT04797780
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.